SPOTLIGHT: Kiadis gets positive Phase II results

Kiadis Pharma has announced positive results from a Phase II clinical trial evaluating Reviroc, which is used to eliminate cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. Release

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.